Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Riggi

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)M Riggi, P Ruffie, S Voisin, et al.
European Urology|November 24, 1999
Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study GroupW P Witjes, M König, F P Boeminghaus, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
Journal of Microscopy|February 14, 2026
A detailed protocol for open and low-cost six-plex immunofluorescence (Flex-6 mIHF) with a proof-of-concept study on breast cancer tissueJulia A M Riggi, Aurélie Daumerie, Naïma Benhaddi, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Influence of pretreatment clinical characteristics on the response rate to mitomycin/vindesine/cisplatin (MVP) in unresectable non-small cell lung cancer. ATTIT (Association pour le Traitement des Tumeurs Intra-Thoraciques)M Riggi, P Ruffie, S Voisin, et al.
European Urology|November 24, 1999
Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study GroupW P Witjes, M König, F P Boeminghaus, et al.
Cancer Research|April 1, 1993
Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor modelJ N Munck, M Riggi, P Rougier, et al.
Journal of Microscopy|February 14, 2026
A detailed protocol for open and low-cost six-plex immunofluorescence (Flex-6 mIHF) with a proof-of-concept study on breast cancer tissueJulia A M Riggi, Aurélie Daumerie, Naïma Benhaddi, et al.
British Journal of Cancer|February 22, 2000
Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicinC Corsini, M Ghielmini, P Mancuso, et al.
Pageof 3